CY1113120T1 - Μεθοδοι, φαρμακευτικες συνθεσεις και ειδη βιομηχανικης παρασκευης για χορηγηση θεραπευτικων κυτταρων στο κεντρικο νευρικο συστημα ζωων - Google Patents

Μεθοδοι, φαρμακευτικες συνθεσεις και ειδη βιομηχανικης παρασκευης για χορηγηση θεραπευτικων κυτταρων στο κεντρικο νευρικο συστημα ζωων

Info

Publication number
CY1113120T1
CY1113120T1 CY20121100643T CY121100643T CY1113120T1 CY 1113120 T1 CY1113120 T1 CY 1113120T1 CY 20121100643 T CY20121100643 T CY 20121100643T CY 121100643 T CY121100643 T CY 121100643T CY 1113120 T1 CY1113120 T1 CY 1113120T1
Authority
CY
Cyprus
Prior art keywords
treatment
cns
cells
methods
types
Prior art date
Application number
CY20121100643T
Other languages
English (en)
Inventor
Ii William H Frey
Lusine Danielyan
Christoph H Gleiter
Original Assignee
Frey Ii, William H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frey Ii, William H. filed Critical Frey Ii, William H.
Publication of CY1113120T1 publication Critical patent/CY1113120T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Μέθοδοι και συνθέσεις για την πρόληψη και αγωγή του κατεστραμμένου και/ή εκφυλισμένου ΚΝΣ βιώνοντας απώλεια ή θάνατο των κυττάρων του ΚΝΣ. Διάφορες ενσωματώσεις της εφεύρεσης μεταφέρουν μία θεραπευτικώς αποτελεσματική ποσότητα, μεταξύ των άλλων, ενός τουλάχιστον θεραπευτικού κυττάρου στο ΚΝΣ μέσω ενδορινικής εφαρμογής στο ανώτερο-τρίτο της ρινικής κοιλότητας, παρακάμπτοντας ως εκ τούτου τον αιματοεγκεφαλικό φραγμό. Μια φαρμακευτική σύνθεση σύμφωνα με την εφεύρεση μπορεί να περιλαμβάνει ένα τουλάχιστον θεραπευτικό κύτταρο, έναν τουλάχιστον παράγοντα επαύξησης-απελευθέρωσης, ένα τουλάχιστον αντιβιοτικό, έναν τουλάχιστον ρυθμιστικό συντελεστή και/ή έναν τουλάχιστον ανοσοκατασταλτικό παράγοντα, όπου η σύνθεση απελευθερώνεται στο ανώτερο-τρίτο της ρινικής κοιλότητας. Τα θεραπευτικά κύτταρα, άπαξ και απελευθερωθούν στο ΚΝΣ, μεταναστεύουν προτιμητέα στην περιοχή καταστροφής ή εκφύλισης ή βλάβης.
CY20121100643T 2007-09-11 2012-07-20 Μεθοδοι, φαρμακευτικες συνθεσεις και ειδη βιομηχανικης παρασκευης για χορηγηση θεραπευτικων κυτταρων στο κεντρικο νευρικο συστημα ζωων CY1113120T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97128407P 2007-09-11 2007-09-11
US12/109,066 US8283160B2 (en) 2007-09-11 2008-04-24 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP08831016A EP2200621B1 (en) 2007-09-11 2008-09-04 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Publications (1)

Publication Number Publication Date
CY1113120T1 true CY1113120T1 (el) 2016-04-13

Family

ID=40432083

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100643T CY1113120T1 (el) 2007-09-11 2012-07-20 Μεθοδοι, φαρμακευτικες συνθεσεις και ειδη βιομηχανικης παρασκευης για χορηγηση θεραπευτικων κυτταρων στο κεντρικο νευρικο συστημα ζωων

Country Status (24)

Country Link
US (3) US8283160B2 (el)
EP (1) EP2200621B1 (el)
JP (2) JP5600294B2 (el)
KR (2) KR20150039197A (el)
CN (2) CN101801397A (el)
AT (1) ATE554778T1 (el)
AU (1) AU2008299124B2 (el)
BR (1) BRPI0816325B8 (el)
CA (1) CA2696892C (el)
CR (1) CR11304A (el)
CY (1) CY1113120T1 (el)
DK (1) DK2200621T3 (el)
ES (1) ES2388403T3 (el)
HR (1) HRP20120560T1 (el)
IL (1) IL204371A (el)
MX (1) MX2010002738A (el)
MY (1) MY154061A (el)
PL (1) PL2200621T3 (el)
PT (1) PT2200621E (el)
RU (1) RU2468818C2 (el)
SG (1) SG184724A1 (el)
SI (1) SI2200621T1 (el)
UA (1) UA98507C2 (el)
WO (1) WO2009035901A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518390B2 (en) * 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US9821149B2 (en) * 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
CN104837987B (zh) 2011-12-23 2018-10-02 德普伊新特斯产品公司 人脐带组织来源的细胞的检测
US20130336928A1 (en) * 2012-06-18 2013-12-19 Healthpartners Research & Education Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s)
FR3001974B1 (fr) 2013-02-08 2016-02-12 Olivier Schussler Procede de purification de cellules
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10279012B2 (en) * 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
CN115120745A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
CA2942172A1 (en) * 2014-03-06 2015-09-11 Children's National Medical Center Treatment of neonatal brain injury with hb-egf
US11413408B2 (en) 2014-07-29 2022-08-16 Peter Edenhoffer Positive pressure inspiration device for delivery of medicaments
CA2956447C (en) * 2014-07-29 2023-04-11 Peter EDENHOFFER Positive pressure inspiration device for delivery of medicaments
US10130657B2 (en) 2015-02-13 2018-11-20 John C. Hughes Formulation, apparatus, and methods for treatment of brain trauma
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
WO2017011326A1 (en) 2015-07-10 2017-01-19 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
CN116196995A (zh) 2015-08-13 2023-06-02 武田药品工业株式会社 用于评估接触系统激活的含有蛋白酶抑制剂的真空采血管
IL305449A (en) 2016-04-15 2023-10-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
CN106924286A (zh) * 2017-02-16 2017-07-07 上海安集协康生物技术股份有限公司 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CN108096280A (zh) * 2017-12-28 2018-06-01 上海安集协康生物技术股份有限公司 一种神经干细胞滴鼻剂
KR20220005900A (ko) * 2020-07-07 2022-01-14 가톨릭대학교 산학협력단 뇌신경계질환 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
AU2049500A (en) * 1998-12-09 2000-06-26 Chiron Corporation Administration of neurotrophic agents to the central nervous system
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
JP3886346B2 (ja) * 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
JP4676442B2 (ja) * 2003-12-02 2011-04-27 セラヴィー バイオサイエンシズ エルエルシー 神経前駆細胞を増殖させるための組成物および方法
WO2007002664A2 (en) * 2005-06-22 2007-01-04 Massachusetts Institute Of Technology Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel
US9456979B2 (en) * 2006-04-27 2016-10-04 Sri International Adminstration of intact mammalian cells to the brain by the intranasal route
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Also Published As

Publication number Publication date
KR20100094450A (ko) 2010-08-26
MY154061A (en) 2015-04-30
AU2008299124A1 (en) 2009-03-19
RU2468818C2 (ru) 2012-12-10
KR20150039197A (ko) 2015-04-09
WO2009035901A1 (en) 2009-03-19
IL204371A (en) 2015-02-26
EP2200621A4 (en) 2011-03-16
CA2696892C (en) 2016-05-17
JP5600294B2 (ja) 2014-10-01
BRPI0816325A2 (pt) 2015-03-24
US20160206554A1 (en) 2016-07-21
BRPI0816325B8 (pt) 2021-05-25
DK2200621T3 (da) 2012-08-06
CR11304A (es) 2010-05-03
US8283160B2 (en) 2012-10-09
HRP20120560T1 (hr) 2012-08-31
PL2200621T3 (pl) 2012-10-31
EP2200621A1 (en) 2010-06-30
BRPI0816325B1 (pt) 2020-04-22
CA2696892A1 (en) 2009-03-19
RU2010113932A (ru) 2011-10-20
JP2014098051A (ja) 2014-05-29
SI2200621T1 (sl) 2012-09-28
MX2010002738A (es) 2010-08-04
SG184724A1 (en) 2012-10-30
JP2010539084A (ja) 2010-12-16
AU2008299124B2 (en) 2013-07-04
CN103181932A (zh) 2013-07-03
PT2200621E (pt) 2012-07-31
US20090068155A1 (en) 2009-03-12
UA98507C2 (ru) 2012-05-25
CN101801397A (zh) 2010-08-11
US20130028874A1 (en) 2013-01-31
KR101504110B1 (ko) 2015-03-19
US9445991B2 (en) 2016-09-20
ATE554778T1 (de) 2012-05-15
EP2200621B1 (en) 2012-04-25
ES2388403T3 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
CY1113120T1 (el) Μεθοδοι, φαρμακευτικες συνθεσεις και ειδη βιομηχανικης παρασκευης για χορηγηση θεραπευτικων κυτταρων στο κεντρικο νευρικο συστημα ζωων
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
BRPI0612125A2 (pt) compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos
EA201590880A1 (ru) Композиции и способы лечения протеинопатий
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2014066916A3 (en) Compositions and methods for safe treatment of rhinitis
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
ATE531377T1 (de) Purin-derivate und anwendungsverfahren
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2010028173A3 (en) Method of treating atrial fibrillation
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
EP3069720A8 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BRPI0518062A (pt) uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
TR201909857T4 (tr) Astım alevlenmesinin önlenmesi ve/veya tedavisi için formoterol ve beklometason dipropionat içeren bir bileşimin kullanımı.
WO2009092892A3 (fr) Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2012061767A3 (en) Defensin-like molecules as novel antimicrobial agents
HK1163526A1 (en) A medicament for treating schizophrenia comprising cilostazol